Peter A. Kiener - 23 Mar 2023 Form 4 Insider Report for Cue Biopharma, Inc. (CUE)

Role: Director
Signature: /s/ Peter Kiener by Colin Sandercock, attorney-in-fact
Issuer symbol: CUE
Transactions as of: 23 Mar 2023
Net transactions value: -$2,895
Form type: 4
Filing time: 27 Mar 2023, 16:05:02 UTC
Previous filing: 05 Jan 2023
Next filing: 23 Jun 2023
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	CUE	Common Stock	Options Exercise	$27,691	+9,682		$2.86	9,682	23 Mar 2023	Direct
transaction	CUE	Common Stock	Sale	$30,586	-9,325	-96%	$3.28	357	23 Mar 2023	Direct	F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	CUE	Stock Option (right to buy)	Options Exercise	$0	-9,682	-9.2%	$0.000000	96,062	23 Mar 2023	Common Stock	9,682	$2.86	Direct	F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Sale to cover exercise price of cashless exercise of stock option.
F2	The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.20 to $3.31, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
F3	This Stock Option became exercisable in five equal annual installments beginning March 23, 2017 and is fully vested. This stock option expired on March 23, 2023.